TARS: Tarsus Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TARS: Tarsus Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,774.65
Enterprise Value ($M) 1,670.15
Book Value ($M) 237.48
Book Value / Share 6.24
Price / Book 7.47
NCAV ($M) 218.30
NCAV / Share 5.71
Price / NCAV 8.13

Profitability (mra)
Return on Invested Capital (ROIC) -0.43
Return on Assets (ROA) -0.50
Return on Equity (ROE) -0.63

Liquidity (mrq)
Quick Ratio 5.38
Current Ratio 5.42

Balance Sheet (mrq) ($M)
Current Assets 357.12
Assets 376.30
Liabilities 138.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2 days ago 13G/A Cormorant Asset Management, LP 1.31 -77.49
2 days ago 13G/A Paradigm Biocapital Advisors LP 6.40 26.61
2 days ago 13G Prudential Financial Inc 6.00
4 days ago 13G Jennison Associates Llc 5.70
4 days ago 13G/A Vanguard Group Inc 5.51 0.00
8 days ago 13G/A BlackRock, Inc. 9.90 0.00
11-06 13G/A Frazier Life Sciences IX, L.P. 4.20 12.02
02-14 13G/A Rtw Investments, Lp 9.50 23.71
02-14 13G/A Tang Capital Partners Lp 6.70 10.15
02-13 13G/A Vivo Capital IX, LLC 2.70 -60.44
02-09 13G Morgan Stanley 5.90
02-02 13G/A TimesSquare Capital Management, LLC 0.00 -100.00
02-02 13G/A Cowen Financial Products LLC 5.77 36.63

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 318,465 1,137,141 28.01
2024-11-14 297,791 1,039,923 28.64
2024-11-13 152,726 690,827 22.11
2024-11-12 140,545 527,386 26.65
2024-11-11 82,543 482,450 17.11

(click for more detail)

Similar Companies
SWTX – SpringWorks Therapeutics, Inc. SYRE – Spyre Therapeutics, Inc.
SYRS – Syros Pharmaceuticals, Inc. TECH – Bio-Techne Corporation
TERN – Terns Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io